LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS;NASDAQ: DDSS) today announced that it will host a conference call on Thursday,February 21 at 8:30 a.m. (ET) to discuss its fourth quarter 2007 financialresults. Labopharm will report its fourth quarter 2007 financial results vianews release at approximately 7:00 a.m. the same day.
To access the conference call by telephone, dial 416-644-3418 or1-800-732-0232. Please connect approximately 15 minutes prior to the beginningof the call to ensure participation. The conference call will be archived forreplay until Thursday, February 28, 2008 at midnight. To access the archivedconference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservationnumber 21260670 followed by the number sign.
A live audio webcast of the conference call will be available atwww.labopharm.com. Please connect at least 15 minutes prior to the conferencecall to ensure adequate time for any software download that may be required tojoin the webcast. The webcast will be archived at the above web site for 30days.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existingsmall molecule drugs using its proprietary controlled-release technologies.The Company's lead product, a unique once-daily formulation of tramadol, isbeing commercially launched in key markets globally. The Company also has arobust pipeline of follow-on products in both pre-clinical and clinicaldevelopment. Labopharm's vision is to become a fully integrated,international, specialty pharmaceutical company with the capability tointernally develop and commercialize its own products. For more information,please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect theCompany's current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein and depend on a number of factors,including the price of the Company's shares, the uncertainties related to theregulatory process for drug approval and the commercialization of theCompany's products, if they are approved. Investors should consult theCompany's ongoing quarterly filings and annual reports for additionalinformation on risks and uncertainties relating to these forward-lookingstatements. The reader is cautioned not to rely on these forward-lookingstatements. The Company disclaims any obligation to update theseforward-looking statements.
SOURCE Labopharm Inc.